She cited reports according to which the UK’s medicines and healthcare products regulatory agency (MHRA) is likely to grant EUA by mid December. A couple of weeks later, she said, the drugs controller general of India (DCGI) could allow it for emergency use in India.
“What I feel is the UK trial has been done on quite a lot of people. If DCGI can draw confidence and comfort from the UK trails, and add Indian data to it, they should be able to give approval in India. This will allow vaccines to be deployed at the earliest,” Shaw told ET.
Her comments came in response to Serum Institute chief executive Adar Poonawalla’s statement that they will be ready with 100 million doses of Oxford vaccine by January. “Hopefully DCGI will give EUA immediately after MHRA in December to start vaccination in India which is the need of the hour,” she tweeted earlier in the day.
The Oxford vaccine candidate has been tested on some 30,000 people in Brazil and the UK, and Indian regulators could add data from whatever tests have been done in the country. “Emergency use authorization in India will be good. We need vaccine-induced herd immunity in many parts of the country where the cases are high. The data shows the transmission rates have come down after its use. I think if we can get EUA in India we can start deploying by early next year,” the Biocon founder said.
“100 Million Doses By January,” Says Adar Poonawalla On Oxford Vaccine – hopefully DCGI will give EUA immediately a… https://t.co/5wIdircCcs
— Kiran Mazumdar-Shaw (@kiranshaw) 1606190281000